News

Azathioprine Therapy in AAV Patients Not Affected by TPMT Enzyme Activity, Study Shows

Compared to patients with inflammatory bowel disorders, the safety and efficacy of azathioprine treatment in ANCA-associated vasculitis (AAV) patients is not affected by lower TPMT protein activity, researchers found. The study, “Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody…

NIH Agency Pioneers Collaborative Research into Rare Diseases

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

Faulty Immune System Component in AAV Leads to Neutrophil Activation, Kidney Damage, Study Shows

A faulty immune system component in patients with active ANCA-associated vasculitis (AAV) is not equipped to stop ANCA-induced neutrophil activation, leading to kidney damage, a Chinese study shows. The component is called complement factor H. The study, titled “Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by…

AAV Patients Have Greater Risk for Cardiovascular Disease, Venous Thromboembolism, Study Finds

Patients with ANCA-associated vasculitis carry a threefold higher risk for cardiovascular disease, and a eightfold greater risk for cerebrovascular accidents, compared to the general population, a long-term study shows. The study, “Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA-Associated Vasculitis: A 20-Year Population-Based Cohort…